Hansoh Pharmaceutical Group Company Limited

Investors are acutely focused on the loss of exclusivity (LOE) of Merck & Co.’s mega-blockbuster Keytruda (pembrolizumab) in 2028, but head of global clinical development and chief medical officer

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. CytomX, Amgen Decision Follows January

Big pharma’s appetite for the next big play in the mega-blockbuster obesity market seems insatiable, but two companies aim to feed their pipelines with sizeable collaborations announced on 3 March. Ab

“Either for young biotech or established pharma companies in China, a combination of innovation and globalization is the trend,” Shan Jiang, chief technology officer at Hansoh Pharmaceutical, told the